Use of the IGF-I Antisense Strategy in the Treatment of the Hepatocarcinoma

Upegui-Gonzalez, Lia C.; Duc, Huynh Thien; Buisson, Y.; Arborio, M.; Lafarge‐Frayssinet, C.; Jasmin, C; Guo, Yajun; Trojan, Jerzy

doi:10.1007/978-1-4615-5357-1_6

Cited by 17 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30][31][32] Furthermore, oligonucleotide antisense therapy against IGF-I mRNA has shown decreased HCC growth rates in vitro and in vivo, indicating a significant role for IGF-I in progression of HCC. 33,34 Most of the effects of IGF-I are exerted through ligand binding to a specific heterodimeric IGF-IR. 18,19 Ligand binding leads to activation of intracytoplasmic tyrosine kinases located on the receptor ␤-chain and receptor autophosphorylation.…”

mentioning

confidence: 99%

Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma

et al. 2002

View full text Add to dashboard Cite

mentioning

confidence: 99%

Insulin-like growth factor I is a comitogen for hepatocyte growth factor in a rat model of hepatocellular carcinoma

et al. 2002

View full text Add to dashboard Cite

“…The arrest of IGF-I expression diminishes or stops neoplastic development [7,29,30] due to the consequential apoptosis and anti-tumor immune response (MHC-I) [31][32][33] . These two phenomena, which play an important role in the mechanism of IGF-I, are barely present (if not non-existent) in other oncoprotein and growth factor mechanisms such as EGF, VEGF, or TGF-beta [34][35][36][37] .…”

Section: Igf-1 Biomarkermentioning

confidence: 99%

IGF-I biomarker testing in an ethical context

Trojan¹,

Aristizábal

Jay³

et al. 2016

Adv Mod Oncol Res

Self Cite

View full text Add to dashboard Cite

Abstract:As we have come to know, there is a connection between cancer biomarkers and genes, along with their susceptibility to a particular disease, all of which have an obvious impact on the clinical practice and development of genetic testing. In any cancer disease, the diagnosis and treatment should be related to the investigation of specific biomarkers (generally antigens and proteins) and their corresponding genes. The study of different antigens such as alpha-fetoprotein, insulin-like growth factor I (IGF-I), insulin-like growth factor II, vascular endothelial growth factor, and epidermal growth factor, as well as their presence in neoplastic cells have demonstrated that IGF-I is an essential target for gene testing and therapeutic purpose. An over-expression of the IGF-I gene in mature tissues is a sign of neoplastic processes, e.g. brain or breast malignancy. A lot of questions have arisen regarding the ethics of gene testing, particularly concerns on the selection of patients for specific growth hormone/insulin-like growth factor I (GHIIGF-I) testing. Evidently, our current society is involved in a process of geneticization -the redefinition of individuals in terms of genetic codes. As such, we should take extreme care when making ethical judgments based on "scientific evidence" derived from genetic testing (typically those involving different biomarkers such as DNA, RNA, chromosomes, and proteins) in relation to genetic abnormalities that could predict current or future diseases. In this situation, the understanding of bioethics is of utmost importance.

show abstract

“…[149][150][151][152][153][154][155] Antisense against N-ras or against the fibroblast growth factor-2 mRNA inhibits the proliferation of HCC in vitro and reduces the tumorigenicity of the cells in the nude mice model. 153 The low proliferative ability and tumorigenic potential of HCC cells treated by antigens anti-IGF-1 has been demonstrated to correlate with apoptosis mechanisms and the induction of an immune response against tumor cells due to IGF-1-mediated re-expression of MHC B7 molecules at the surface of tumor cells.…”

Section: Playing With the Biological Activation Pathwaysmentioning

confidence: 99%

“…153 The low proliferative ability and tumorigenic potential of HCC cells treated by antigens anti-IGF-1 has been demonstrated to correlate with apoptosis mechanisms and the induction of an immune response against tumor cells due to IGF-1-mediated re-expression of MHC B7 molecules at the surface of tumor cells. 150,154 Most of the reported results depict experiments performed with HCC cells manipulated ex vivo to overexpress the antisense oligonucleotide inhibitor prior to be reinjected in the animal, which does not reflect the therapeutical potential of this approach.…”

Section: Playing With the Biological Activation Pathwaysmentioning

confidence: 99%